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Objective
Recently, the bone marrow was shown to be a site were T
cells are primed against blood borne antigens and tumor
associated antigens. The common tumor-associated anti-
gen (TAA) MUC1 has been shown to be expressed on
about 90% of malignant plasma cells in multiple mye-
loma (MM). This study was performed to investigate the
content and reactivity of MUC-1 specific memory T cells
in BM compared to PB from MM patients with respect to
possible use in immunotherapeutic strategies.
Methods
Paired BM and PB samples from 42 HLA-A2 pos. MM
patients and 11 HLA-A2 pos. normal donors were tested
for frequency of TAA-specific CD8 T cells by HLA-A2
tetramer-analysis using MUC1 derived peptide LLLTVLTV
(12–20) as TAA or for frequency of tumor-reactive CD8
memory T cells in 40 h short term IFNy ELISPOT assay.
Antigen specific cytotoxic potential of 6 patients T cells
was evaluated by Chr51 chromium release assay following
single restimulation with MUC1 peptide pulsed DCs.
Presence of MUC1 expressing cells and CD8 T cells in BM
biopsies from MM patients was detected by immunohis-
tochemistry.
Results
The frequencies of MUC1-specific CD8 T cells in PB and
BM of 42 tested patients varied between 0–6.4% of CD8 T
cells. In contrast, PB and BM of 11 normal donors con-
tained only 0–0.25% tetramer binding CD8 T cells.
Enrichment of MUC1 specific CD8 T cells (> 0.3% of CD8
T cells) was found in PB and BM from 16 out of 30
patients (53%).
Using short term IFNγ ELISPOT functional-assay we
detected enrichment of MUC1-reacticve CD8 memory T
cells in BM from 6 out of 12 patients (50%). In contrast,
in corresponding PB, MUC1-reactive T cells were detected
in only 1 out of 9 patients (11%). The frequencies of
MUC1-reactive CD8 memory T cells varied between
1:390–1:3350 (BM) and 1:3340 (PB). BMTCs from MM
patients were able to kill MUC1-peptide loaded Target
cells in a dose dependent manner in contrast to corre-
sponding PB T cells from the same patients. CD8 T cells
were co-localized together with MUC1 expressing cells in
the BM of MM patients.
Conclusions
MUC1 specific T cells are highly enriched in PB and BM of
about 50% of MM patients indicating induction and
maintainance of tumor cell directed immune responses
during the course of disease. We detected high amounts of
MUC1-derived peptide specific CD8 memory T cells capa-
ble of IFNγ secretion and cytotoxicity upon appropriate
restimulation in BM but not PB of MM patients. Thus,
autologous BM-derived memory T cells reactivated in vitro
with MUC1 pulsed dendritic cells might be useful for
future immunotherapy of MM.
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